Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2016

View Archived Issues

SIK2 shows potential to discriminate aggressive from indolent prostate cancer

Clinical results inidcate pro-BNP as a clozapine management biomarker

Centrexion acquires analgesic candidates from Boehringer Ingelheim

Eisai transfers rights to E-7777 to Dr. Reddy's in the U.S., Europe and certain emerging markets

Celimmune initiates phase II study of AMG-714 for refractory celiac disease type II

Positive results from pivotal phase III study of Aplidin for multiple myeloma

Origent Data Sciences and Cytokinetics collaborate on predictive analytics model in ALS

Oncodesign patents RIP-2 kinase inhibitors

Genocea reports 12-month efficacy data from phase II trial of GEN-003 for genital herpes

Bristol-Myers Squibb discloses inhibitors of HIV replication

BCHT initiates clinical trials of influenza vaccine in China

CalAsia Pharmaceuticals develops HSP90/TRAP1 inhibitors

Samumed presents Wnt signaling inhibitors

RedHill reports interim results from phase IIa study of RHB-104 for relapsing-remitting MS

National Chiao Tung University divulges EGFR inhibitors

NIAID grants supports Karyopharm's preclinical evaluation of KPT-350 for SLE

DiaSorin to acquire Focus Diagnostics' molecular and immunoassay product business

Daiichi Sankyo seeks Japanese approval for hydromorphone hydrochloride

Eisai Inc. to transfer AkaRx shares to PBM Capital

Promising topline data from two phase III trials of dupilumab in atopic dermatitis

TFE3 shows potential as a diagnostic marker for solid pseudopapillary neoplasm

Teva and Takeda announce establishment of Teva Takeda Yakuhin in Japan

EphA4 may be useful to predict CCRT response in rectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...